NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212
Bitget2026/09/28 21:01- NeOnc Technologies will hold an in-person FDA End-of-Phase 1 Type B meeting on Nov. 17, 2026, for NEO212.
- Discussion will cover Phase 2 study design, dose selection, endpoints, and evidence needed to support a future marketing application.
- NeOnc will also seek FDA feedback on whether its proposed development plan could support an accelerated approval pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.
Bitcoin Crash Warning Goes Viral as X Post Flags Benner Cycle
"New High" WLD rises to $0.6177, reaching a nearly 3-month peak
Crypto prices
More
